SCHEMBL29506508

SCHEMBL29506508

CN1CCN(c2ccc(Nc3ncc4c(n3)N3CCN=C3N(c3ccccc3Cl)C4=O)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 12/20 0.55
▸ TNK2 Q07912 1/20 0.53
▸ ALK Q9UM73 1/20 0.52
▸ FGFR4 P22455 2/20 0.50
▸ SRC P12931 2/20 0.50
▸ FGFR1 P11362 1/20 0.50
▸ FGFR2 P21802 1/20 0.50
▸ FGFR3 P22607 1/20 0.50
▸ CCNK O75909 1/20 0.49
▸ CCNA2 P20248 1/20 0.49
▸ CDK2 P24941 1/20 0.49
▸ CCND3 P30281 1/20 0.49
▸ CDK9 P50750 1/20 0.49
▸ CDK6 Q00534 1/20 0.49
▸ JAK2 O60674 1/20 0.48
▸ DCLK1 O15075 1/20 0.48
▸ LRRK2 Q5S007 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ AXL P30530 1/20 0.47
▸ NEK2 P51955 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20180608 1.00 WEE1 (0.55) WEE1TNK2ALKFGFR4SRC
SCHEMBL29506492 0.94 WEE1 (0.55) WEE1TNK2ALKFGFR4SRC
SCHEMBL21373290 0.94 WEE1 (0.55) WEE1TNK2ALKFGFR4SRC
SCHEMBL20180746 0.91 WEE1 (0.62) WEE1ALKFGFR4SRCFGFR1
SCHEMBL29506538 0.91 WEE1 (0.62) WEE1ALKFGFR4SRCFGFR1
SCHEMBL21373340 0.90 WEE1 (0.54) WEE1TNK2ALKFGFR4SRC
SCHEMBL29506555 0.90 WEE1 (0.54) WEE1TNK2ALKFGFR4SRC
SCHEMBL21373383 0.90 WEE1 (0.51) WEE1TNK2ALKFGFR4SRC
SCHEMBL29506544 0.90 WEE1 (0.51) WEE1TNK2ALKFGFR4SRC
SCHEMBL21373412 0.89 CDK4 (0.54) WEE1TNK2ALKFGFR4SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback